Your browser doesn't support javascript.
loading
Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?
Costa, Francesco; Brugaletta, Salvatore; Pernigotti, Alberto; Flores-Ulmanzor, Eduardo; Ortega-Paz, Luis; Cequier, Angel; Iniguez, Andres; Serra, Antoni; Jiménez-Quevedo, Pilar; Mainar, Vicente; Campo, Gianluca; Tespili, Maurizio; den Heijer, Peter; Bethencourt, Armando; Vazquez, Nicolás; van Es, Gerrit Anne; Backx, Bianca; Valgimigli, Marco; Serruys, Patrick; Sabaté, Manel.
Afiliação
  • Costa F; Instituto Clínico Cardiovascular (ICCV), Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain (F.C., S.A.P., E.F.-U., L.O.-P., M.S.).
  • Brugaletta S; Department of Clinical and Experimental Medicine, University of Messina, Italy (F.C.).
  • Pernigotti A; Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain (F.C.).
  • Flores-Ulmanzor E; Instituto Clínico Cardiovascular (ICCV), Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain (F.C., S.A.P., E.F.-U., L.O.-P., M.S.).
  • Cequier A; Instituto Clínico Cardiovascular (ICCV), Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain (F.C., S.A.P., E.F.-U., L.O.-P., M.S.).
  • Iniguez A; Instituto Clínico Cardiovascular (ICCV), Hospital Clínic i Provincial de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain (F.C., S.A.P., E.F.-U., L.O.-P., M.S.).
  • Jiménez-Quevedo P; Hospital Álvaro Cunqueiro - Vigo, Spain (A.I.).
  • Mainar V; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (A.I.).
  • Tespili M; University Hospital San Carlos, Madrid, Spain (P.J.-Q.).
  • den Heijer P; Hospital General of Alicante, Spain (V.M.).
  • Bethencourt A; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona (FE), Italy (G.C.).
  • Vazquez N; Maria Cecilia Hospital, GVM Care and Research, Cotignola, RA, Italy (G.C.).
  • van Es GA; University Hospital Bolognini Seriate, Bergamo, Italy (M.T.).
  • Backx B; Amphia Ziekenhuis, Breda, the Netherlands (P.d.H.).
  • Valgimigli M; Hospital Son Espases, Palma de Mallorca, Spain (A.B.).
  • Serruys P; Hospital Juan Canalejo, A Coruña, Spain (N.V.).
  • Sabaté M; Cardialysis, Rotterdam, the Netherlands (G.A.v.E., B.B.).
Circ Cardiovasc Interv ; 12(9): e007705, 2019 09.
Article em En | MEDLINE | ID: mdl-31451013
ABSTRACT

BACKGROUND:

Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal stents (BMS), and international guidelines recommend their use as first line treatment. Yet, BMS are still widely used in practice, especially in large coronary vessels. We aimed to compare efficacy and safety of second-generation DES over BMS in large coronary culprit ST-segment elevated myocardial infarction lesions.

METHODS:

We evaluated impact of large coronary stents (maximum size ≥3.50 mm) or smaller stents (<3.50 mm), among 1498 patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention, randomly allocated to everolimus-eluting DES or to an equivalent BMS platform in the EXAMINATION trial (Clinical Evaluation of the Xience-V Stent in Acute Myocardial Infarction Trial). Clinical events up to 5 years of follow-up were evaluated.

RESULTS:

Large coronary stents were used in 683 patients (45.9%). At 5-year follow-up, the crude rate of the primary end point, a composite of all-cause death, any myocardial infarction, or any revascularization, was similar among patients treated with large or smaller coronary stents. The impact of DES versus BMS implantation was consistent irrespective of the stent size both for the primary end point (Pint=0.82) and other secondary ischemic end points. Within patients treated with bigger stents, DES implantation was associated to a trend toward a reduction of target lesion (hazard ratio, 0.53; 95% CI, 0.27-1.02; P=0.05) and target vessel revascularization (hazard ratio, 0.60; 95% CI, 0.34-1.03; P=0.066).

CONCLUSIONS:

Our results do not support the preferential use of BMS for patients with large coronary vessels. DES may warrant improved efficacy irrespective of stent size among patients undergoing primary percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION URL https//www.clinicaltrials.gov. Unique identifier NCT00828087.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Stents / Stents Farmacológicos / Intervenção Coronária Percutânea / Infarto do Miocárdio com Supradesnível do Segmento ST / Metais Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circ Cardiovasc Interv Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Stents / Stents Farmacológicos / Intervenção Coronária Percutânea / Infarto do Miocárdio com Supradesnível do Segmento ST / Metais Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circ Cardiovasc Interv Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2019 Tipo de documento: Article